TY - JOUR T1 - Combined HRT increased CV events more than placebo but did not differ from oestrogen HRT after menopause JF - Evidence Based Medicine JO - Evid Based Med SP - 52 LP - 52 DO - 10.1136/ebm.13.2.52 VL - 13 IS - 2 A2 - , Y1 - 2008/04/01 UR - http://ebm.bmj.com/content/13/2/52.abstract N2 - A H MacLennanDr A H MacLennan, University of Adelaide, Adelaide, South Australia, Australia; alastair.maclennan@adelaide.edu.auDesign:randomised controlled trial (Women’s International Study of long Duration Oestrogen after Menopause [WISDOM]).Allocation:concealed.*Blinding:blinded ({patients, healthcare providers}†, and outcome assessors).*Setting:384 general practices in the UK, 91 in Australia, and 24 in New Zealand.Patients:5692 women, 50–69 years of age (mean age 63 y), who were postmenopausal and achieved 80% compliance during a 12-week run-in period. Exclusion criteria included previous breast cancer; cancer other than basal or squamous cell skin cancer within the past 10 years; endometriosis or endometrial hyperplasia; venous thromboembolism (VTE); current gall stones; and ⩾1 of the following within the past 6 months—myocardial infarction (MI), unstable angina, cerebrovascular accident, subarachnoid haemorrhage, transient ischaemic attack, or … ER -